Search Results 271-280 of 16553 for ������������KA���:ZA31���24������ ���������������������������������
Jacksonville, Florida: 24-000012; Scottsdale/Phoenix, Arizona: 24-000012. NCT ID: NCT06106308. Sponsor Protocol Number: CRDF-004. About this study. The ...
2017 Aug 24; 19 (10):92. View PubMed; Vasile VC, Jaffe AS. Natriuretic Peptides and Analytical Barriers. Clin Chem. 2017 Jan; 63 (1):50-58 Epub 2016 Oct 10
About this study. This open-label study will evaluate safety, pharmacokinetics and efficacy of a 12 or 24 week regimen of ombitasvir/ABT-450/ritonavir and ...
... 24 than treatment with Best Available Therapy, and a greater proportion of patients achieving a ≥ 50% reduction in total symptom score from baseline to ...
- To assess the relationship between clinical effects (adverse event [AE] and/or tumor response) and CD38 receptor density at baseline (Part A). Participation ...
About this study. The purpose of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm ...
Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways ...
The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...
Life expectancy < 24 months due to associated non-cardiac co-morbid conditions; Other medical, social, or psychological conditions that in the opinion of an ...
Lee YS, Khan AA. Financial Toxicity for Female Patients with Urinary Incontinence. Curr Urol Rep. 2023 Jan; 24(1):33-39. Epub 2022 Dec 17.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.